¿Tuberculosis, o pérdida del cabello? La necesidad de replantear las prioridades de la investigación médica

PRINCETON – En un mundo ideal, la cantidad de fondos que destinamos a la investigación médica para prevenir o curar una enfermedad sería proporcional a su seriedad y al número de personas que la padecen. En el mundo real, el 90% del dinero utilizado para investigación médica se centra en males que son responsables de apenas el 10% de las muertes y discapacidad causadas por enfermedades en todo el globo.

En otras palabras, las enfermedades que causan 9 décimas partes de lo que la Organización Mundial de la Salud denomina "la carga global de enfermedades" reciben apenas un décimo del esfuerzo de investigación médica del mundo. Como resultado, millones de personas mueren cada año por males para los que no se están desarrollando nuevos medicamentos, mientras que las compañías farmacéuticas destinan miles de millones a desarrollar curas para la disfunción eréctil y la calvicie.

Sin embargo, culpar a las farmacéuticas es una respuesta demasiado fácil. No pueden justificar el desarrollo de nuevos medicamentos, a menos que puedan esperar recuperar los costes con las ventas. Si destinan sus esfuerzos a enfermedades que afectan a personas adineradas, o a gente que vive en países con seguros de salud nacionales, podrán patentar cualquier nuevo medicamento que descubran. Durante los 20 años que dura la patente, tendrán el monopolio sobre su venta y estarán en posición de cobrar altos precios por él.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.


Log in

  1. An employee works at a chemical fiber weaving company VCG/Getty Images

    China in the Lead?

    For four decades, China has achieved unprecedented economic growth under a centralized, authoritarian political system, far outpacing growth in the Western liberal democracies. So, is Chinese President Xi Jinping right to double down on authoritarianism, and is the “China model” truly a viable rival to Western-style democratic capitalism?

  2. The assembly line at Ford Bill Pugliano/Getty Images

    Whither the Multilateral Trading System?

    The global economy today is dominated by three major players – China, the EU, and the US – with roughly equal trading volumes and limited incentive to fight for the rules-based global trading system. With cooperation unlikely, the world should prepare itself for the erosion of the World Trade Organization.

  3. Donald Trump Saul Loeb/Getty Images

    The Globalization of Our Discontent

    Globalization, which was supposed to benefit developed and developing countries alike, is now reviled almost everywhere, as the political backlash in Europe and the US has shown. The challenge is to minimize the risk that the backlash will intensify, and that starts by understanding – and avoiding – past mistakes.

  4. A general view of the Corn Market in the City of Manchester Christopher Furlong/Getty Images

    A Better British Story

    Despite all of the doom and gloom over the United Kingdom's impending withdrawal from the European Union, key manufacturing indicators are at their highest levels in four years, and the mood for investment may be improving. While parts of the UK are certainly weakening economically, others may finally be overcoming longstanding challenges.

  5. UK supermarket Waring Abbott/Getty Images

    The UK’s Multilateral Trade Future

    With Brexit looming, the UK has no choice but to redesign its future trading relationships. As a major producer of sophisticated components, its long-term trade strategy should focus on gaining deep and unfettered access to integrated cross-border supply chains – and that means adopting a multilateral approach.

  6. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now